Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 4Stomach Neoplasms 1Rare Tumour 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Locally Advanced Prostate Cancer 1Limited Stage Small Cell Lung Cancer 1Hereditary leiomyomatosis and renal cell cancer 1HER2-negative Breast Cancer 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

enzalutamide 3testosterone 17 beta-cypionate 2darolutamide 2abiraterone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1pamiparib 1olaparib 1lactitol 1fluciclovine F-18 1enfortumab vedotin 1cabazitaxel 1avelumab 1Standard of Care 1Selegiline 1Prednisolone 1Pluvicto 1PSMA-617 1Gonadotropin-Releasing Hormone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-resistant Prostate Cancer × pamiparib × Clear all
NCT05327621 2022-04-14

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡